相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inflammatory cues enhance TGFβ activation by distinct subsets of human intestinal dendritic cells via integrin αvβ8
T. M. Fenton et al.
MUCOSAL IMMUNOLOGY (2017)
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials
Giandomenico Roviello et al.
EUROPEAN JOURNAL OF CANCER (2017)
Pharmacologic Blockade of αvβ1 Integrin Ameliorates Renal Failure and Fibrosis In Vivo
Yongen Chang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial
Jacob Elkins et al.
LANCET NEUROLOGY (2017)
The opposing roles of laminin-binding integrins in cancer
Veronika Ramovs et al.
MATRIX BIOLOGY (2017)
The high price of anticancer drugs: origins, implications, barriers, solutions
Vinay Prasad et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Prophylactic orthosteric inhibition of leukocyte integrin CD11b/CD18 prevents long-term fibrotic kidney failure in cynomolgus monkeys
Abbas Dehnadi et al.
NATURE COMMUNICATIONS (2017)
Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation
Ines Gonzalez-Suarez et al.
BRAIN AND BEHAVIOR (2017)
Modulating angiogenesis with integrin-targeted nanomedicines
Aroa Duro-Castano et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors
Tufia Haddad et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Conformational equilibria and intrinsic affinities define integrin activation
Jing Li et al.
EMBO JOURNAL (2017)
Milestones of the last 10 years CNS cancer
Christine Marosi et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2017)
Arginine-Glycine-Aspartate-Binding Integrins as Therapeutic and Diagnostic Targets
Cui-Cui Sun et al.
AMERICAN JOURNAL OF THERAPEUTICS (2016)
The complexity of integrins in cancer and new scopes for therapeutic targeting
Hellyeh Hamidi et al.
BRITISH JOURNAL OF CANCER (2016)
Medical isotope supply raises concerns
Carolyn Brown
CANADIAN MEDICAL ASSOCIATION JOURNAL (2016)
Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges
Francesca Tartari et al.
CANCER TREATMENT REVIEWS (2016)
Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer
Maha Hussain et al.
CLINICAL CANCER RESEARCH (2016)
αvβ3 Integrin and tumour blood vessels - learning from the past to shape the future
Fevzi Demircioglu et al.
CURRENT OPINION IN CELL BIOLOGY (2016)
Etrolizumab for ulcerative colitis: the new kid on the block?
Jitin Makker et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
B. Milojkovic Kerklaan et al.
INVESTIGATIONAL NEW DRUGS (2016)
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies
Geert A. Cirkel et al.
INVESTIGATIONAL NEW DRUGS (2016)
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial
Mustafa Khasraw et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis
Nicolas V. Currier et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Integrin-based therapeutics: biological basis, clinical use and new drugs
Klaus Ley et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
State Initiatives to Control Medication Costs - Can Transparency Legislation Help?
Ameet Sarpatwari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease
Victor L. Perez et al.
OCULAR SURFACE (2016)
Endosomes: Emerging Platforms for Integrin-Mediated FAK Signalling
Jonna Alanko et al.
TRENDS IN CELL BIOLOGY (2016)
Integrin αvβ6 and matrix metalloproteinase 9 correlate with survival in gastric cancer
Pei-Long Lian et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
Michael Weller et al.
ONCOTARGET (2016)
Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health
Tomas A. Moreno et al.
SEMINARS IN OPHTHALMOLOGY (2016)
Integrins in the Spotlight of Cancer
Daniela Bianconi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease
P. Luthra et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
J. Vansteenkiste et al.
ANNALS OF ONCOLOGY (2015)
Dual-Action Combination Therapy Enhances Angiogenesis while Reducing Tumor Growth and Spread
Ping-Pui Wong et al.
CANCER CELL (2015)
Latent TGF-β-binding proteins
Ian B. Robertson et al.
MATRIX BIOLOGY (2015)
Tumour exosome integrins determine organotropic metastasis
Ayuko Hoshino et al.
NATURE (2015)
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
Elizabeth R. Gerstner et al.
NEURO-ONCOLOGY (2015)
End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma
Warren P. Mason
NEURO-ONCOLOGY (2015)
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
L. Burt Nabors et al.
NEURO-ONCOLOGY (2015)
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease Results of the Randomized Phase III OPUS-2 Study
Joseph Tauber et al.
OPHTHALMOLOGY (2015)
Targeting the TGFβ pathway for cancer therapy
Cindy Neuzillet et al.
PHARMACOLOGY & THERAPEUTICS (2015)
The αvβ1 integrin plays a critical in vivo role in tissue fibrosis
Nilgun I. Reed et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Alpha2beta1 integrin in cancer development and chemoresistance
Dalila Naci et al.
SEMINARS IN CANCER BIOLOGY (2015)
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
Anne-Florence Blandin et al.
FRONTIERS IN PHARMACOLOGY (2015)
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs
Sham Mailankody et al.
JAMA ONCOLOGY (2015)
Leukocyte arrest: Biomechanics and molecular mechanisms of β2 integrin activation
Zhichao Fan et al.
BIORHEOLOGY (2015)
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
E. ELez et al.
ANNALS OF ONCOLOGY (2015)
Sulfonamide inhibitors of α2β1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation
Liisa Nissinen et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Targeting Integrin and Integrin Signaling in Treating Thrombosis
Brian Estevez et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Redox Modulation of Adjacent Thiols in VLA-4 by AS101 Converts Myeloid Leukemia Cells from a Drug-Resistant to Drug-Sensitive State
Adi Layani-Bazar et al.
CANCER RESEARCH (2014)
A Multicenter Phase 1 Study of EMD 525797 (DI17E6), a Novel Humanized Monoclonal Antibody Targeting αv Integrins, in Progressive Castration-resistant Prostate Cancer with Bone Metastases After Chemotherapy
Manfred Wirth et al.
EUROPEAN UROLOGY (2014)
Atomic Basis for the Species-specific Inhibition of αV Integrins by Monoclonal Antibody 17E6 Is Revealed by the Crystal Structure of αV β3 Ectodomain-17E6 Fab Complex
Bhuvaneshwari Mahalingam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Strategies To Inhibit Tumor Associated Integrin Receptors: Rationale for Dual and Multi-Antagonists
Helen M. Sheldrake et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Therapeutic Targeting of Integrin αvβ6 in Breast Cancer
Kate M. Moore et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Targeting Integrin α6 Stimulates Curative-Type Bone Metastasis Lesions in a Xenograft Model
Terry H. Landowski et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al.
LANCET ONCOLOGY (2014)
Antithrombotic drugs market
Kritika Chaudhari et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
PRISMA-Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Man Cai Wang et al.
MEDICINE (2014)
Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease
Shunsuke Minagawa et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
Roy van der Meel et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Inhibition of αvβ6 Promotes Acute Renal Allograft Rejection in Nonhuman Primates
D. J. Lo et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human α? integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
A. Heidenreich et al.
ANNALS OF ONCOLOGY (2013)
Inhibition of Recall Responses Through Complementary Therapies Targeting CD8(+) T-Cell- and Alloantibody-Dependent Allocytotoxicity in Sensitized Transplant Recipients
Jason M. Zimmerer et al.
CELL TRANSPLANTATION (2013)
αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma
Anne Ducassou et al.
EUROPEAN JOURNAL OF CANCER (2013)
The V3/V5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model
Timo L. M. ten Hagen et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
αv-Integrin isoform expression in primary human tumors and brain metastases
Alexander Vogetseder et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
How Natalizumab Binds and Antagonizes α4 Integrins
Yamei Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal 18F-FDG PET and gene expression analysis
Maren Bretschi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Longitudinal Expression Analysis of αv Integrins in Human Gliomas Reveals Upregulation of Integrin αvβ3 as a Negative Prognostic Factor
Jens Schittenhelm et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2013)
Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs
Neil C. Henderson et al.
NATURE MEDICINE (2013)
A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo
C. Eberlein et al.
ONCOGENE (2013)
TGF-β and αvβ6 Integrin Act in a Common Pathway to Suppress Pancreatic Cancer Progression
Aram F. Hezel et al.
CANCER RESEARCH (2012)
Volociximab in cancer
Salah Almokadem et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Complexities of TGF-β Targeted Cancer Therapy
Erin C. Connolly et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
A phase I study of continuous infusion cilengitide in patients with solid tumors
Peter H. O'Donnell et al.
INVESTIGATIONAL NEW DRUGS (2012)
Raise standards for preclinical cancer research
C. Glenn Begley et al.
NATURE (2012)
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
Kevin B. Kim et al.
MELANOMA RESEARCH (2012)
Integrins as therapeutic targets
Simon L. Goodman et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab)
Larry D. Sasich et al.
SAUDI PHARMACEUTICAL JOURNAL (2012)
Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye
Min Zhong et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors
Simon L. Goodman et al.
BIOLOGY OPEN (2012)
Regulation of Integrin Activation
Chungho Kim et al.
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 27 (2011)
Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions
Jochen G. Schneider et al.
BONE (2011)
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma
S. O'Day et al.
BRITISH JOURNAL OF CANCER (2011)
Switching TGFβ from a tumor suppressor to a tumor promoter
Gareth J. Inman
CURRENT OPINION IN GENETICS & DEVELOPMENT (2011)
Efalizumab
Marina Talamonti et al.
EXPERT OPINION ON DRUG SAFETY (2011)
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer
Katherine M. Bell-McGuinn et al.
GYNECOLOGIC ONCOLOGY (2011)
Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study
Tobias Baeuerle et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Stable Coordination of the Inhibitory Ca2+ Ion at the Metal Ion-Dependent Adhesion Site in Integrin CD11b/CD18 by an Antibody-Derived Ligand Aspartate: Implications for Integrin Regulation and Structure-Based Drug Design
Bhuvaneshwari Mahalingam et al.
JOURNAL OF IMMUNOLOGY (2011)
Integrin Structure, Activation, and Interactions
Iain D. Campbell et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2011)
Blocking TGF beta via Inhibition of the alpha v beta 6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease
Tamiko R. Katsumoto et al.
INTERNATIONAL JOURNAL OF RHEUMATOLOGY (2011)
Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
Carlos Mas-Moruno et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2010)
Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3 integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases
Mark A. Rosenthal et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2010)
A Randomized Phase 2 Study of Etaracizumab, a Monoclonal Antibody Against Integrin αvβ3, ± Dacarbazine in Patients With Stage IV Metastatic Melanoma
Peter Hersey et al.
CANCER (2010)
Integrin-TGF-β crosstalk in fibrosis, cancer and wound healing
Coert Margadant et al.
EMBO REPORTS (2010)
TGF-β inactivation and TGF-α overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer
Ji Yeon Baek et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
An LFA-1 (alpha(L)beta(2)) Small-Molecule Antagonist Reduces Inflammation and Joint Destruction in Murine Models of Arthritis
Suzanne J. Suchard et al.
JOURNAL OF IMMUNOLOGY (2010)
A double agent in cancer: Stopping macrophages wounds tumors
Joseph E. Qualls et al.
NATURE MEDICINE (2010)
Eptifibatide is noninferior to abciximab: implications for clinical practice
Alexandra King
Nature Reviews Cardiology (2010)
Antiplatelet therapies for the treatment of cardiovascular disease
Alan D. Michelson
NATURE REVIEWS DRUG DISCOVERY (2010)
Integrins as therapeutic targets: lessons and opportunities
Dermot Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Steven M. Paul et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Assessing Long-Term Drug Safety: Lessons (Re) Learned from Raptiva
Nicole M. Seminara et al.
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2010)
Structural basis of transmembrane domain interactions in integrin signaling
Tobias S. Ulmer
CELL ADHESION & MIGRATION (2010)
Integrins in cancer: biological implications and therapeutic opportunities
Jay S. Desgrosellier et al.
NATURE REVIEWS CANCER (2010)
Efalizumab A Review of its Use in the Management of Chronic Moderate-to-Severe Plaque Psoriasis
James E. Frampton et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2009)
Integrin α2 Mediates Selective Metastasis to the Liver
Kiyoshi Yoshimura et al.
CANCER RESEARCH (2009)
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
Tom Mikkelsen et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
Christine A. Iacobuzio-Donahue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
How Tysabri survived
Brady Huggett
NATURE BIOTECHNOLOGY (2009)
Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors
Andrew R. Reynolds et al.
NATURE MEDICINE (2009)
Inhibition of integrin alpha v beta 6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis
Khalid Puthawala et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
The GPIIb/IIIa (integrin αIIbβ3) odyssey:: a technology-driven saga of a receptor with twists, turns, and even a bend
Barry S. Coller et al.
BLOOD (2008)
Antibody-mediated blockade of integrin αvβ6 inhibits tumor progression in vivo by a transforming growth factor-β-regulated mechanism
Louise A. Koopman Van Aarsen et al.
CANCER RESEARCH (2008)
Loss of E-cadherin promotes ovarian cancer metastasis via alpha(5)-integrin, which is a therapeutic target
Kenjiro Sawada et al.
CANCER RESEARCH (2008)
Transforming Growth Factor β: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer?
Li Yang et al.
CANCER RESEARCH (2008)
Monotherapy with anti-LFA-1 monoclonal antibody promotes long-term survival of rat islet xenografts
Eric B. Tredget et al.
CELL TRANSPLANTATION (2008)
Integrin ανβ6 acts as a prognostic indicator in gastric carcinoma
Z. -Y. Zhang et al.
CLINICAL ONCOLOGY (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells
Qiming Chen et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors
Catherine Delbaldo et al.
INVESTIGATIONAL NEW DRUGS (2008)
Structure and mechanics of integrin-based cell adhesion
M. Amin Arnaout et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival
S. Hazelbag et al.
JOURNAL OF PATHOLOGY (2007)
A peptide selected by biopanning identifies the integrin αvβ6 as a prognostic biomarker for nonsmall cell lung cancer
Anissa N. Elayadi et al.
CANCER RESEARCH (2007)
alpha v beta 6 integrin regulates renal fibrosis and inflammation in Alport mouse
Kyungmin Hahm et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
Helmut Friess et al.
BMC CANCER (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Scar wars: is TGF beta the phantom menace in scleroderma?
Andrew Leask
ARTHRITIS RESEARCH & THERAPY (2006)
Angiogenesis as a therapeutic target
N Ferrara et al.
NATURE (2005)
Brief report - Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
BK Kleinschmidt-DeMasters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
A Langer-Gould et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Expression and function of laminins in the embryonic and mature vasculature
R Hallmann et al.
PHYSIOLOGICAL REVIEWS (2005)
Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI)
R Sandberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma
RC Bates et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Integrin-mediated activation of latent transforming growth factor beta
D Sheppard
CANCER AND METASTASIS REVIEWS (2005)
The molecular portrait of in vitro growth by meta-analysis of gene-expression profiles
R Sandberg et al.
GENOME BIOLOGY (2005)
Negative regulation of EGFR signalling through integrin-alpha(1)beta(1)-mediated activation of protein tyrosine phosphatase TCPTP
E Mattila et al.
NATURE CELL BIOLOGY (2005)
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis
V Viglietta et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1
CF Lu et al.
JOURNAL OF IMMUNOLOGY (2004)
Integrin β3 regions controlling binding of murine mAb 7E3:: Implications for the mechanism of integrin αIIbβ3 activation
A Artoni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Immunohistochemical screening for β6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro
B Sipos et al.
HISTOPATHOLOGY (2004)
The collagen receptor subfamily of the integrins
DJ White et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2004)
Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in β3-integrin-deficient mice
AR Reynolds et al.
CANCER RESEARCH (2004)
CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo
M Trikha et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics
T Xiao et al.
NATURE (2004)
Integrin α2β1 inhibits Fas-mediated apoptosis in T lymphocytes by protein phosphatase 2A-dependent activation of the MAPK/ERK pathway
S Gendron et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Therapeutic antagonists and conformational regulation of integrin function
M Shimaoka et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Integrin αIIbβ3 and its antagonism
MJ Quinn et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours
FALM Eskens et al.
EUROPEAN JOURNAL OF CANCER (2003)
Comparative pharmacology of GP IIb/IIIa antagonists
K Schrör et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2003)
Structures of the αL I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation
M Shimaoka et al.
CELL (2003)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Coming to grips with integrin binding to ligands
MA Arnaout et al.
CURRENT OPINION IN CELL BIOLOGY (2002)
Integrins: Bidirectional, allosteric signaling machines
RO Hynes
CELL (2002)
Rapid leukocyte integrin activation by chemokines
C Laudanna et al.
IMMUNOLOGICAL REVIEWS (2002)
The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1
DZ Mu et al.
JOURNAL OF CELL BIOLOGY (2002)
Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand
JP Xiong et al.
SCIENCE (2002)
Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors
AA Weber et al.
THROMBOSIS RESEARCH (2002)
Glycoprotein IIb/IIIa antagonists - from bench to practice
IP Casserly et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2002)
Enhanced pathological angiogenesis in mice lacking beta(3) integrin or beta(3) and beta(5) integrins
LE Reynolds et al.
NATURE MEDICINE (2002)
Crystal structure of the extracellular segment of integrin αVβ3
JP Xiong et al.
SCIENCE (2001)
Eptifibatide and 7E3, but not tirofiban, inhibit αvβ3 integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin
M Lele et al.
CIRCULATION (2001)
Multiple discontinuous ligand-mimetic antibody binding sites define a ligand binding pocket in integrin αIIbβ3
W Puzon-McLaughlin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
